Olaparib hydroxybenzoic acid cocrystals and their pharmaceutical uses
Novel olaparib:hydroxybenzoic acid co-crystals address solubility and stability issues, enabling effective treatment of various diseases with improved delivery methods and reduced side effects.
Patent Information
- Application Number
- JP2024527319
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-10
- Filing Date
- 2022-11-10
- Publication Date
- 2024-11-21
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing forms of olaparib, a PARP inhibitor, suffer from low solubility and bioavailability, leading to large capsule sizes and severe side effects, and alternative crystalline forms face issues of polymorphic instability and hygroscopicity, limiting their use in inhalation and other delivery methods.
Development of novel 1:1 and 2:1 olaparib:hydroxybenzoic acid co-crystals, characterized by specific XRPD and infrared peaks, which exhibit improved solubility and stability, allowing for various pharmaceutical formulations including inhalable and topical applications.
The co-crystals enhance solubility and stability, enabling effective treatment of diverse diseases with reduced side effects and improved patient compliance through multiple delivery methods.
Smart Images

Figure 2024543371000022 
Figure 2024543371000023 
Figure 2024543371000024
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 63 / 277,773 (filed November 10, 2021), the disclosure of which is incorporated by reference.
[0002] The present disclosure relates to olaparib hydroxybenzoic acid cocrystals, therapeutic uses of said cocrystals, and pharmaceutical compositions containing them. [Background technology]
[0003] Olaparib (4-[(3-{[4(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2H)-one (below)) is an inhibitor of the enzyme poly(ADP-ribose) polymerase (PARP). Its synthesis was first described in WO2004080976. [ka]
[0004] Olaparib is currently marketed by AstraZeneca under the brand name Lynparza® for the treatment of adults with suspected harmful germline or somatic BRCA gene mutations in ovarian, breast or pancreatic cancer, or suspected harmful germline or somatic homologous recombination repair (HRR) gene mutations in prostate cancer.
[0005] As stated in the European Medicines Agency (EMA) CHMP assessment report (EMA / CHMP / 789139 / 2014), olaparib is classified as a class 4 drug by the Biopharmaceutical Classification System (BCS), which means that it has both low solubility and low permeability. Therefore, to achieve full efficacy, it is essential to find a form of olaparib with the highest possible solubility and bioavailability. Olaparib exists in multiple polymorphic forms, as well as solvated and hydrated forms, which are disclosed, for example, in WO2008 / 04708 (form A), WO2009 / 050469 (form L), WO2010 / 041051, WO2017 / 123156, and WO2017 / 40283. The first marketed formulation contains form A, which has an aqueous solubility of about 0.1 mg / ml and is pH independent. Due to the low solubility of the polymorphic crystalline forms of Olaparib, formulations that enhance solubility were required to achieve sufficient bioavailability. The first commercial formulation was a capsule, where Olaparib Form A was micronized and formulated as a crystalline dispersion in a semi-solid lauroyl macrogolglyceride (LMG) matrix. Although this formulation improved the bioavailability of pure crystalline Olaparib, only 50 mg capsules were achieved due to the amount of LMG required for the formulation. Clinical trials showed that the effective dose of Olaparib was 400 mg twice daily, resulting in patients needing 16 capsules per day. In addition, the capsule size was large (size 0) due to the amount of excipients required. It was also found that Olaparib can occur in various polymorphic forms, even when the same solvent or solvent mixture is used. For example, WO2009 / 050469 and WO2008 / 04708 show that both ethanol / water and methanol / water can produce both Form A and Form L (both anhydrous forms), whereas water alone can produce olaparib hydrate (Form H). Furthermore, different solvents can produce different solvates, and mixed solvents can produce mixed solvates in different ratios (WO2017 / 40283). Thus, it is difficult to control the exact form of olaparib produced using a particular method.In 2018, AstraZeneca had to recall a lot of olaparib capsules after it was found to contain levels of form L above specified limits, and several other lots have been recalled due to concerns that the amount of form L could increase during the capsules' shelf life. Therefore, there is a need for new crystalline forms of olaparib that do not exist in multiple polymorphic forms and that do not undergo form conversion or generate solvated or hydrated forms during storage.
[0006] More recently, a novel tablet formulation has been developed to overcome some of these limitations. The tablet formulation contains an amorphous solid dispersion of olaparib in a matrix of copovidone polymer and is formed using a melt extrusion process. The novel tablet showed more rapid dissolution than the capsule formulation and subsequently higher bioavailability, resulting in a reduction in the daily dose of olaparib from 800 mg to 600 mg. Although the use of an amorphous form of olaparib also overcame the polymorphic conversion issue, this approach also poses several drawbacks: 1) metastable amorphous forms are generally less stable in terms of storage than crystalline forms, and therefore large amounts of stabilizers are required to maintain the amorphous form. 2) Amorphous forms are always at risk of recrystallization during storage. 3) The polymer (copovidone) used in the tablet matrix is hygroscopic, so the tablet formulation requires protective packaging to prevent moisture uptake. It would therefore be preferable to find an alternative crystalline form of olaparib that can provide high solubility like the amorphous form, but without the inherent low stability of the amorphous form and without the need for stabilizers.
[0007] In the last few years, the enzyme PARP has been found to play an important role in several non-oncological diseases (C. Szabo et al., (2018) 175: 1932-222). PARP has been shown to be associated with pulmonary inflammatory diseases (e.g., asthma, COPD, and acute lung injury (ALI)) as well as other inflammatory conditions (e.g., arthritis and colitis). It has also been found to be a major contributing factor in neurodegenerative diseases (e.g., Parkinson's disease and Alzheimer's disease), cardiovascular conditions (e.g., myocardial ischemia / reperfusion injury, various forms of heart failure, cardiomyopathies, circulatory shock, cardiovascular aging, diabetic cardiovascular complications, myocardial hypertrophy, atherosclerosis, vascular remodeling after injury, and atherosclerosis). PARP is involved in several ophthalmic diseases (e.g., retinal degeneration, diseases of the retina or optic nerve, and glaucoma) (US6444676). PARP has been shown to be a key mediator in the progression of multiple types of fibrosis, including pulmonary, cardiac, hepatic, and renal fibrosis, which would suggest that olaparib may be used to treat many non-oncological conditions.
[0008] However, orally delivered olaparib has multiple tolerable side effects (including nausea, vomiting, fatigue, and anemia) that can often be severe. Developing alternative delivery methods that allow for local administration of olaparib, allowing treatment with minimal systemic exposure, may allow olaparib to be repurposed for new diseases with a lower risk of side effects and increase patient compliance. Also, given the wide range of diseases for which olaparib may have therapeutic benefit, and the different types of patients and the specific body sites that require treatment, patients would benefit from having multiple delivery methods for olaparib administration that best meet their needs. Pharmaceutical compositions can include, for example, oral inhalation compositions, ophthalmic compositions, topical compositions, or transdermal compositions. For example, inhalation formulations allow for the treatment of pulmonary diseases (e.g., pulmonary fibrosis, asthma, COPD, and ALI) without the side effects of oral administration. However, amorphous drug forms that require large amounts of stabilizing polymers and are hygroscopic, or crystalline forms that are subject to polymorphic instability, are not suitable for inhalation delivery. However, the known crystalline forms of Olaparib have low solubility, making ophthalmic or transdermal formulations unlikely, and therefore new crystalline forms of Olaparib that combine good stability and enhanced solubility are needed to enable alternative formulations of Olaparib to treat new PARP-mediated diseases.
[0009] The most common alternative crystal forms used to improve the solubility of low-solubility drugs are pharma- ceutically acceptable salts. Crystalline salts are formed when a drug and a second component crystallize together to form a two-component crystal complex held together by ionic bonds, and proton transfer occurs between the two components. Drug salts often have better physical properties than the pure crystalline drug. However, olaparib is non-ionizable and therefore cannot form salts. For non-ionic drugs, the formation of a co-crystal is an alternative two-component crystal complex in which the drug and the second component are held together by non-ionic bonds (e.g., hydrogen bonds or van der Waals bonds), and proton exchange does not occur between the two components. The second component of the co-crystal is referred to as a "co-former." Co-crystals of drugs have unique crystal structures with distinctive crystallographic and spectroscopic properties compared to the drug and co-former individually. Such multi-component aggregates continue to excite and are particularly useful within the pharmaceutical field. Cocrystals of drugs often have more favorable pharmaceutical properties than the pure drug, and therefore are often suitable for new drug delivery options that are not possible with either the pure crystalline drug or its amorphous form. This is because cocrystal forms may have improved properties (e.g., improved dissolution or solubility properties, or favorable storage stability, melting point, hygroscopicity, or other physicochemical properties). For pharmaceutical cocrystals of olaparib to be acceptable as an alternative commercial form of olaparib, it is important that the coformer used is "inert" and acceptable from a regulatory point of view for use in pharmaceutical formulations. A 1:1 olaparib-urea cocrystal has been previously disclosed in CN105753789. However, this patent only discloses one cocrystal of olaparib, and there remains a need for other medically acceptable cocrystals of olaparib with greater improvement in dissolution rate and less hygroscopicity. The 1:1 olaparib-fumaric acid cocrystal and the 1:1 olaparib-3,5-dihydroxybenzoic acid cocrystal were previously disclosed in WO2021 / 044437, the 1:1 olaparib-maleic acid cocrystal were previously disclosed in CN111689905, and the 1:1 olaparib-malonic acid cocrystal were previously disclosed in CN111825621.However, these cocrystals could not be reproduced using the methods disclosed in the above publications. Summary of the Invention
[0010] The present invention relates to a novel 1:1 olaparib:hydroxybenzoic acid cocrystal, wherein the hydroxybenzoic acid of the 1:1 olaparib:hydroxybenzoic acid cocrystal is a compound of formula (I): [ka] In the formula, n=0 or 1; However, when n=1, the hydroxyl groups are not located at the 3- and 5-positions of the benzene ring.
[0011] The present invention also relates to a novel 2:1 olaparib:hydroxybenzoic acid co-crystal, wherein the hydroxybenzoic acid of the 2:1 olaparib:hydroxybenzoic acid co-crystal is a compound of formula (II): [ka] In the formula, n=0 or 1.
[0012] The 2:1 olaparib:hydroxybenzoic acid cocrystal may be water-free (anhydrous) or optionally hydrated. The 2:1 olaparib:hydroxybenzoic acid cocrystal may contain varying amounts of water depending on conditions such as humidity, and typically contains an average of up to about 3 waters of hydration.
[0013] For example, in the case of a 2:1 olaparib:hydroxybenzoic acid cocrystal of the invention, the cocrystal can contain up to about 1 water of hydration, up to about 2 waters of hydration, up to about 3 waters of hydration, or an average number of waters of hydration.
[0014] Exemplary hydroxybenzoic acid coformers can include gentisic acid, 2,4-dihydroxybenzoic acid, 4-hydroxybenzoic acid, salicylic acid, or 3,4-dihydroxybenzoic acid.
[0015] In particular, the olaparib hydroxybenzoic acid cocrystals of the present invention relate to 1:1 olaparib gentisic acid cocrystal, 2:1 olaparib gentisic acid cocrystal, 1:1 olaparib 2,4-dihydroxybenzoic acid cocrystal, 2:1 olaparib 2,4-dihydroxybenzoic acid cocrystal, 2:1 olaparib 4-hydroxybenzoic acid cocrystal, 1:1 olaparib salicylic acid cocrystal, and 1:1 olaparib 3,4-dihydroxybenzoic acid cocrystal.
[0016] The present invention also relates to a pharmaceutical composition comprising the olaparib hydroxybenzoic acid cocrystal of the present invention and a pharma- ceutically acceptable carrier. The olaparib hydroxybenzoic acid cocrystal of the present invention can be used in the same manner as olaparib. Olaparib is useful for treating diseases that benefit from inhibition of poly(ADP-ribose) polymerase (PARP). Such diseases include cancer, fibrosis, inflammatory conditions (e.g., asthma, COPD, colitis, arthritis), neurological diseases (e.g., neurodegeneration, neurotrauma, stroke), cardiovascular conditions, ocular degenerative diseases, vascular diseases (e.g., diabetic complications, atherosclerosis), and various forms of critical illness (e.g., septic shock, ALI, acute liver failure). Thus, the olaparib hydroxybenzoic acid cocrystal of the present invention may be useful for treating such diseases, disorders, and conditions. [Brief description of the drawings]
[0017] [Figure 1] 1 shows the XRPD pattern of 1:1 olaparib gentisic acid cocrystal. [Diagram 2] 1 shows a DSC trace of a 1:1 olaparib gentisic acid cocrystal. [Diagram 3] 1 shows a TGA trace of 1:1 olaparib gentisic acid co-crystal. [Figure 4] 1 shows the infrared spectrum of 1:1 olaparib gentisic acid cocrystal. [Diagram 5] 1 shows the XRPD pattern of 2:1 olaparib gentisic acid cocrystal. [Figure 6]1 shows a DSC trace of the 2:1 olaparib gentisic acid cocrystal. [Figure 7] 1 shows a TGA trace of 2:1 olaparib gentisic acid co-crystal. [Figure 8] 1 shows the infrared spectrum of 2:1 olaparib gentisic acid cocrystal. [Figure 9] 1 shows a GVS isotherm graph of the 2:1 olaparib gentisic acid cocrystal. [Figure 10] 1 shows the XRPD pattern of the 1:1 olaparib 2,4-dihydroxybenzoic acid co-crystal. [Figure 11] 1 shows a DSC trace of the 1:1 olaparib 2,4-dihydroxybenzoic acid cocrystal. [Figure 12] 1 shows a TGA trace of 1:1 olaparib 2,4-dihydroxybenzoic acid co-crystal. [Figure 13] 1 shows the infrared spectrum of 1:1 olaparib 2,4-dihydroxybenzoic acid cocrystal. [Figure 14] 1 shows the XRPD pattern of the 2:1 olaparib 2,4-dihydroxybenzoic acid cocrystal. [Figure 15] 1 shows a DSC trace of the 2:1 olaparib 2,4-dihydroxybenzoic acid cocrystal. [Figure 16] 1 shows a TGA trace of 2:1 olaparib 2,4-dihydroxybenzoic acid co-crystal. [Figure 17] 1 shows the infrared spectrum of the 2:1 olaparib 2,4-dihydroxybenzoic acid cocrystal. [Figure 18] 1 shows a GVS isotherm graph of the 2:1 olaparib 2,4-dihydroxybenzoic acid cocrystal. [Figure 19] 1 shows the XRPD pattern of the 2:1 olaparib 4-hydroxybenzoic acid cocrystal. [Figure 20] 1 shows a DSC trace of the 2:1 olaparib 4-hydroxybenzoic acid cocrystal. [Figure 21] 1 shows a TGA trace of the 2:1 olaparib 4-hydroxybenzoic acid co-crystal. [Figure 22] 1 shows the infrared spectrum of the 2:1 olaparib 4-hydroxybenzoic acid cocrystal. [Diagram 23] 1 shows a GVS isotherm graph of the 2:1 olaparib 4-hydroxybenzoic acid cocrystal. [Figure 24] 1 shows the XRPD pattern of 1:1 olaparib-salicylic acid cocrystal. [Diagram 25] 1 shows a DSC trace of the 1:1 olaparib salicylic acid cocrystal. [Figure 26] 1 shows a TGA trace of 1:1 olaparib salicylic acid cocrystal. [Figure 27] 1 shows the XRPD pattern of the 1:1 olaparib-3,4-dihydroxybenzoic acid cocrystal. [Figure 28] 1 shows a DSC trace of 1:1 olaparib-3,4-dihydroxybenzoic acid cocrystal. [Figure 29] 1 shows a TGA trace of 1:1 olaparib-3,4-dihydroxybenzoic acid co-crystal. [Diagram 30] 1 shows the H NMR spectrum of the 1:1 olaparib-3,4-dihydroxybenzoic acid co-crystal. [Diagram 31] 1 shows the dissolution profiles in FaSSIF (V2) at 37° C. for 1:1 olaparib gentisic acid co-crystal, 2:1 olaparib gentisic acid co-crystal, 1:1 olaparib 2,4-dihydroxybenzoic acid co-crystal, 2:1 2,4-dihydroxybenzoic acid co-crystal, 2:1 olaparib 4-hydroxybenzoic acid co-crystal, crystalline olaparib Form A (as supplied), and micronized crystalline olaparib Form A. [Diagram 32] Shown is an XRPD overlay of the 2:1 olaparib·gentisic acid cocrystal, the 2:1 2,4-dihydroxybenzoic acid cocrystal, and the 2:1 olaparib·4-hydroxybenzoic acid cocrystal. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0018] The present invention relates to a novel 1:1 olaparib:hydroxybenzoic acid cocrystal, wherein the hydroxybenzoic acid of the 1:1 olaparib:hydroxybenzoic acid cocrystal is a compound of formula (I): [ka] In the formula, n=0 or 1; However, when n=1, the hydroxyl groups are not located at the 3- and 5-positions of the benzene ring.
[0019] The present invention also relates to a novel 2:1 olaparib:hydroxybenzoic acid co-crystal, wherein the hydroxybenzoic acid of the 2:1 olaparib:hydroxybenzoic acid co-crystal is a compound of formula (II): [ka] In the formula, n=0 or 1.
[0020] The 2:1 olaparib:hydroxybenzoic acid cocrystal may be water-free (anhydrous) or optionally hydrated. The 2:1 olaparib:hydroxybenzoic acid cocrystal may contain varying amounts of water depending on conditions such as humidity, and typically contains an average of up to about 3 waters of hydration.
[0021] For example, in the case of a 2:1 olaparib:hydroxybenzoic acid cocrystal of the invention, the cocrystal can contain up to about 1 water of hydration, up to about 2 waters of hydration, up to about 3 waters of hydration, or an average number of waters of hydration.
[0022] Exemplary hydroxybenzoic acid coformers can include gentisic acid, 2,4-dihydroxybenzoic acid, 4-hydroxybenzoic acid, salicylic acid, or 3,4-dihydroxybenzoic acid.
[0023] In particular, the olaparib hydroxybenzoic acid cocrystals of the present invention relate to 1:1 olaparib gentisic acid cocrystal, 2:1 olaparib gentisic acid cocrystal, 1:1 olaparib 2,4-dihydroxybenzoic acid cocrystal, 2:1 olaparib 2,4-dihydroxybenzoic acid cocrystal, 2:1 olaparib 4-hydroxybenzoic acid cocrystal, 1:1 olaparib salicylic acid cocrystal, and 1:1 olaparib 3,4-dihydroxybenzoic acid cocrystal.
[0024] The 2:1 olaparib:hydroxybenzoic acid cocrystal of the present invention is uniquely isostructural. The 2:1 olaparib:hydroxybenzoic acid cocrystal of the present invention is characterized by common peaks in a powder X-ray diffraction pattern, at least two, at least three, at least four, or all of which are selected from the peaks at 6.2, 10.3, 11.6, 13.5, and 17.8°2θ±0.2°2θ. The 2:1 olaparib:hydroxybenzoic acid cocrystal of the present invention is characterized by a powder X-ray diffraction pattern substantially similar to FIG. 5, FIG. 14, or FIG. 19. The common peaks of the 2:1 olaparib:hydroxybenzoic acid cocrystal of the present invention are illustrated in FIG. 32, which shows an overlay of powder X-ray diffraction patterns.
[0025] The 2:1 olaparib:hydroxybenzoic acid cocrystal of the invention is characterized by common peaks in the infrared spectrum, with at least two, at least three, at least four, or all of these peaks being at 1014, 1222, 1243, 1435, and 1590 cm. -1 ±1cm -1 The 2:1 olaparib:hydroxybenzoic acid cocrystal of the present invention is characterized by an infrared spectrum substantially similar to that of Figures 8, 17, or 22.
[0026] These olaparib hydroxybenzoic acid cocrystals of the invention, their preparation, and their characterization are described in the following examples and illustrated in the figures. The invention relates to pharmaceutical compositions comprising a therapeutically effective amount of the olaparib hydroxybenzoic acid cocrystals of the invention and one or more pharma- ceutically acceptable carriers. The invention also relates to methods of treating the diseases, disorders, and conditions described herein, and the use of an effective amount of or a pharmaceutical composition comprising the olaparib hydroxybenzoic acid cocrystal of the invention for the treatment thereof. The invention further provides the use of the olaparib hydroxybenzoic acid cocrystals of the invention in the manufacture of a medicament for use in the treatment of the diseases, disorders, and conditions described herein.
[0027] Therapeutic Uses of Olaparib Hydroxybenzoate Cocrystals
[0028] As discussed above, olaparib is known in the art to be useful for treating various diseases, disorders, and conditions.Therefore, the olaparib hydroxybenzoic acid cocrystal, 1:1 olaparib gentisic acid cocrystal, 2:1 olaparib gentisic acid cocrystal, 1:1 olaparib 2,4-dihydroxybenzoic acid cocrystal, 2:1 olaparib 2,4-dihydroxybenzoic acid cocrystal, 2:1 olaparib 4-hydroxybenzoic acid cocrystal, 1:1 olaparib salicylic acid cocrystal, 1:1 olaparib 3,4-dihydroxybenzoic acid cocrystal, and pharmaceutical compositions containing them of the present invention can also be used to treat such diseases, disorders, and conditions. Diseases, disorders, or conditions that can be treated with the olaparib hydroxybenzoic acid cocrystals of the present invention include, but are not limited to, cancer, fibrosis, inflammatory conditions (e.g., asthma, COPD, colitis, arthritis), neurological diseases (e.g., neurodegeneration, neurotrauma, stroke), cardiovascular conditions, ocular degenerative diseases, vascular diseases (e.g., diabetic complications, atherosclerosis), and various forms of critical illness (e.g., septic shock, ALI, acute liver failure).
[0029] Accordingly, the present invention relates to methods of treating such diseases, disorders, or conditions comprising administering a therapeutically effective amount of an olaparib hydroxybenzoic acid cocrystal of the invention to a patient in need thereof, or administering a therapeutic composition comprising an olaparib hydroxybenzoic acid cocrystal of the invention to a patient in need thereof.
[0030] The term "treatment" or "treating" refers to any treatment of a disease, disorder, or condition in a mammal, including preventing or protecting against a disease, disorder, or condition, i.e., not developing clinical symptoms, inhibiting a disease, disorder, or condition, i.e., arresting or suppressing the development of clinical symptoms, and / or alleviating a disease, disorder, or condition, including relieving discomfort associated with the condition or disorder, i.e., reducing clinical symptoms. Those skilled in the art will appreciate that in human medicine, it is not always possible to distinguish between "prevention" and "suppression", since the eventual inciting event(s) may be unknown or latent, or the patient may not be identified until some time after the occurrence of the event(s). Thus, as used herein, the term "prevention" is intended as an element of "treatment" that encompasses both "prevention" and "suppression" of a disease, disorder, or condition. The term "protection" is intended to include "prevention".
[0031] Another aspect of the present invention relates to the use of the olaparib hydroxybenzoic acid cocrystals of the present invention in the treatment of the aforementioned diseases, disorders, and conditions. Accordingly, the present invention further relates to the manufacture of a medicament for use in the treatment of such diseases, disorders, and conditions.
[0032] Pharmaceutical Compositions Comprising Olaparib Hydroxybenzoic Acid Cocrystals
[0033] The present invention relates to pharmaceutical compositions comprising, consisting essentially of, or consisting of a therapeutically effective amount of the olaparib hydroxybenzoic acid cocrystals of the present invention and a pharma- ceutical acceptable carrier (also referred to as a pharma- ceutical acceptable excipient). As mentioned above, these pharmaceutical compositions are therapeutically useful in treating or preventing disorders such as those discussed above. The pharmaceutical compositions of the present invention may be solid dosage forms or liquid formulations made with the olaparib hydroxybenzoic acid cocrystals of the present invention.
[0034] The pharmaceutical composition of the present invention can be in any pharmaceutical form comprising the olaparib hydroxybenzoic acid cocrystal of the present invention. The pharmaceutical composition can be, for example, a tablet, a capsule, an oral solution, an injectable composition, a topical composition, an inhalation composition, or a transdermal composition. Liquid pharmaceutical compositions can be prepared using the olaparib hydroxybenzoic acid cocrystal of the present invention and represent certain embodiments of the present invention. For liquid pharmaceutical compositions, the olaparib hydroxybenzoic acid cocrystal of the present invention can be dissolved in a solvent (e.g., water) and provided to a patient as a solution, or can be provided in a dry form to be prepared into a solution at the time of treatment.
[0035] Typically, the pharmaceutical composition comprises, for example, about 0.1% to about 99.9% by weight of the olaparib hydroxybenzoic acid cocrystal of the present invention, for example, about 0.5% to about 99.5% by weight of the olaparib hydroxybenzoic acid cocrystal of the present invention, and, for example, 99.5% to 0.5% by weight of at least one suitable pharmaceutical excipient or solvent. In one embodiment, the composition can be about 5% to about 75% by weight of the olaparib hydroxybenzoic acid cocrystal of the present invention, with the remainder being at least one suitable pharmaceutical excipient, solvent, or at least one other adjuvant, as discussed below.
[0036] A "therapeutically effective amount" of the olaparib hydroxybenzoic acid cocrystal of the present invention is an amount that correlates with a therapeutic effect, and may be, for example, about 5 mg to about 2000 mg, about 50 mg to about 1500 mg, about 100 mg to about 1000 mg, about 250 mg to about 750 mg, or about 500 mg. The actual amount required to treat any particular disease, disorder, or condition for any particular patient may depend on a variety of factors, including, for example, the particular disease, disorder, or condition being treated, the disease state being treated and its severity, the particular pharmaceutical composition used, the patient's age, weight, general health, sex, and diet, mode of administration, time of administration, route of administration, rate of excretion, duration of treatment, any drugs used in combination or concomitantly with the particular compound being used, and other such factors well known in the medical arts. These factors are discussed in Goodman and Gilman, "The Pharmacological Basis of Therapeutics," Tenth Edition, A. Gilman, J. Hardman and L. Limbird, eds., McGraw-Hill Press, 155-173, 2001, incorporated herein by reference.
[0037] Depending on the type of pharmaceutical composition, the pharma- ceutically acceptable carrier can be selected from any one or combination of carriers known in the art. The choice of pharma- ceutically acceptable carrier depends on the pharmaceutical form used and the desired method of administration. For the pharmaceutical composition of the present invention, i.e., a pharmaceutical composition comprising the olaparib hydroxybenzoic acid cocrystal of the present invention, a carrier that maintains the crystalline form should be selected. In other words, the carrier should not substantially alter the olaparib hydroxybenzoic acid cocrystal, nor should the carrier be otherwise incompatible with the olaparib hydroxybenzoic acid cocrystal of the present invention used, for example, by producing undesirable biological effects or otherwise adversely interacting with any other component(s) of the pharmaceutical composition.
[0038] The pharmaceutical compositions of the present invention can be prepared by methods known in the pharmaceutical formulation art. See, for example, Remington's Pharmaceutical Sciences, 18th Ed., (Mack Publishing Company, Easton, Pa., 1990), incorporated herein by reference. In solid dosage forms, the olaparib hydroxybenzoic acid cocrystals of the present invention can be formulated with at least one pharma- ceutical acceptable excipient (e.g., sodium citrate or dicalcium phosphate), or with at least one of the following: (a) fillers or extenders (e.g., starch, lactose, sucrose, glucose, mannitol, and silicic acid), (b) binders (e.g., cellulose derivatives, starch, alginates, gelatin, polyvinylpyrrolidone, sucrose, and gum arabic), (c) humectants (e.g., glycerol), (d) disintegrants (e.g., agar, calcium carbonate, potato, or tapioca), (e.g., glycerol ... The pharmaceutical composition of the present invention may be mixed with (e) liquid retarders (e.g., paraffin), (f) absorption promoters (e.g., quaternary ammonium compounds), (g) wetting agents (e.g., cetyl alcohol, glycerol monostearate, magnesium stearate, etc.), (h) adsorbents (e.g., kaolin and bentonite), and (i) lubricants (e.g., talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, or mixtures thereof). In the case of capsules, tablets, and pills, the dosage form may also include a buffering agent. Pharmaceutically acceptable adjuvants known in the field of pharmaceutical formulations may also be used in the pharmaceutical composition of the present invention. Such adjuvants include, but are not limited to, preservatives, wetting agents, suspending agents, sweetening agents, flavoring agents, aromatic agents, emulsifying agents, and dispensing agents. Prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol, sorbic acid, etc. It may also be desirable to include isotonic agents (for example, sugars, sodium chloride, etc.).The pharmaceutical compositions of the present invention, if desired, can also contain minor amounts of auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, antioxidants and the like, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylated hydroxytoluene, and the like.
[0039] Such solid dosage forms can be prepared with coatings and shells (e.g., enteric coatings) as are known in the pharmaceutical art. These may contain pacifying agents and may be of such a composition as to release the active compound(s) in a delayed manner at a certain part of the intestinal tract. Non-limiting examples of embedding compositions that may be used include polymeric substances and waxes. The active compound may also be in a microencapsulated form (e.g., pellets) with one or more of the above excipients, if appropriate.
[0040] Suspensions may contain, in addition to the active compound, suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, or mixtures of these substances. Liquid dosage forms may be aqueous and may contain pharma- ceutically acceptable solvents, as well as conventional liquid dosage form excipients known in the art, including, but not limited to, buffers, flavoring agents, sweeteners, preservatives, and stabilizers.
[0041] Compositions for rectal administration are, for example, suppositories, which can be prepared by mixing the olaparib hydroxybenzoic acid cocrystals of the present invention with a suitable non-irritating excipient or carrier (e.g., cocoa butter, polyethylene glycol, or a suppository wax); the suppositories may be solid at ordinary temperature and liquid at body temperature and therefore melt in a suitable body cavity where they release the active ingredient.
[0042] Compositions suitable for topical administration include liquid or semi-liquid preparations, such as liniments, lotions, gels, paints, oil-in-water or water-in-oil emulsions (e.g., creams, ointments, pastes, or foams), or solutions or suspensions (e.g., drops), as known in the art. The compositions of the present invention may be intended for topical administration, in which case the carrier may suitably comprise a solution, emulsion, ointment, or gel base. The carrier or base may, for example, comprise one or more of the following: petrolatum, lanolin, polyethylene glycol, beeswax, mineral oil, diluents (e.g., water and alcohol), and emulsifiers and stabilizers. Viscosifiers may be present in pharmaceutical compositions for topical administration. When intended for transdermal administration, the compositions may comprise transdermal patches or iontophoresis devices. Topical formulations may comprise a concentration of the compounds of the present invention of about 0.1 to about 10% w / v (weight per unit volume).
[0043] In addition to the topical administration methods described above, there are various ways to administer the olaparib hydroxybenzoic acid cocrystals of the present invention locally to the lung. One such means includes a dry powder inhalation formulation of particles of suitable size for inhalation, typically <10 μm (i.e., in the respirable range), composed of the olaparib hydroxybenzoic acid cocrystals of the present invention, which are inhaled by the patient undergoing treatment. Representations of dry powder inhalers can be unit dose capsules or blisters, multi-unit dose representations, or reservoir representations. Representations can include the drug alone or can include a pharma- ceutically acceptable carrier material as a bulking agent to which particles of the olaparib hydroxybenzoic acid cocrystals of the present invention can adhere. The carrier particles can be any acceptable pharmacologically inert material or combination of materials. For example, the carrier particles may be composed of one or more materials selected from sugar alcohols, polyols (e.g., sorbitol, mannitol, or xylitol), and crystalline sugars (including monosaccharides and disaccharides), inorganic salts (e.g., sodium chloride and calcium carbonate), organic salts (e.g., sodium lactate), and other organic compounds (e.g., urea, polysaccharides (e.g., cyclodextrins and dextrins)). The carrier particles may also be crystalline sugars (e.g., monosaccharides such as glucose or arabinose, or disaccharides such as maltose, saccharose, dextrose, or lactose). Another means of localized administration of the olaparib hydroxybenzoic acid cocrystals of the invention to the lung includes delivery via a nebulizer or spray (e.g., generated from a jet nebulizer, vibrating mesh nebulizer, or ultrasonic nebulizer) via a solution made from the cocrystals of the invention, or a suspension of drug particles formulated in a suitable aqueous-based vehicle acceptable for inhalation. The vehicle can include excipients that are acceptable for inhalation, such as mannitol, glycerol, buffers (e.g., phosphate buffers or citrate buffers), sodium chloride, surfactants, and stabilizers. The particles generated from the solution or suspension can be liquid or solid, and are of a size small enough to pass through the oral cavity and larynx into the lungs upon inhalation.Additional means of administering the olaparib hydroxybenzoic acid cocrystals of the invention locally to the lung include non-aqueous pressurized solutions or suspensions delivered via a metered dose inhaler. The olaparib hydroxybenzoic acid cocrystals of the invention may be dissolved or suspended in a formulation that may contain propellants, co-solvents, stabilizers, and other excipients known in the art for formulating these dosage forms.
[0044] In addition to the topical administration methods described above, there are various ways in which the olaparib hydroxybenzoic acid cocrystals of the present invention may be administered systemically in such a manner. One such means involves the patient undergoing treatment inhaling an aerosol suspension of respirable particles composed of the olaparib hydroxybenzoic acid cocrystals of the present invention. It is believed that the olaparib hydroxybenzoic acid cocrystals of the present invention are absorbed into the bloodstream via the lungs in pharmacologic amounts. The respirable particles may be liquid or solid, and the particle size is small enough to pass through the oral cavity and larynx upon inhalation.
[0045] Since the crystalline form of the olaparib hydroxybenzoic acid cocrystal of the present invention can be maintained during preparation, a solid dosage form is one embodiment of the pharmaceutical composition of the present invention. Dosage forms for oral administration can be used, including capsules, tablets, pills, powders, granules, and suspensions. Dosage forms for pulmonary administration can be used, including metered dose inhalers, dry powder inhalers, or nebulizer formulations. For such solid dosage forms, the active compound can be mixed with at least one inert pharma- ceutically acceptable excipient (also known as a pharma-ceutically acceptable carrier).
[0046] The olaparib hydroxybenzoic acid cocrystals of the present invention can also be used to formulate liquid or injectable pharmaceutical compositions. The olaparib hydroxybenzoic acid cocrystals of the present invention in pure form or in a suitable pharmaceutical composition can be administered via any accepted mode of administration or agent to perform a similar utility. Thus, administration can be via, for example, the following routes: oral, buccal, nasal, pulmonary, parenteral (intravenous, intramuscular, or subcutaneous), topical, transdermal, vaginal, intravesical, systemic, ocular, or rectal, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms (solutions, emulsions, or suspensions made from the cocrystals of the present invention) (e.g., tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, sprays, or aerosols, etc.), for example, in unit dosage forms or multiple unit dosage forms suitable for simple administration of precise dosages. One route of administration can be oral, using a convenient daily dosing regimen that can be adjusted depending on the severity of the condition to be treated.
[0047] The present invention also relates to a method of preparing a liquid pharmaceutical composition comprising dissolving the olaparib hydroxybenzoic acid cocrystal of the present invention in a pharma- ceutical acceptable solvent, and to the liquid pharmaceutical composition prepared according to said method. As discussed above, the liquid pharmaceutical composition of the present invention can be administered orally, parenterally, by inhalation, and intravenously. EXAMPLES
[0048] The following analytical methods were used to characterize the olaparib hydroxybenzoic acid cocrystals of the present invention.
[0049] Bruker D8 X-ray Powder Diffraction (XRPD) Characterization: Powder X-ray diffraction patterns of the samples were acquired on a Bruker D8 diffractometer using Cu Ka radiation (40 kV, 40 mA) and a θ-2θ goniometer fitted with a Ge monochromator. The incident beam passes through a 2.0 mm divergence slit, then a 0.2 mm anti-scatter slit and a knife edge. The diffracted beam passes through an 8.0 mm receiving slit and a 2.5° Soller slit, then a Lynxeye detector. The software used for data collection was Diffrac Plus XRD Commander, and the software used for data analysis was Diffrac Plus EVA. Samples were run under ambient conditions over an angular range of 2°-42°2θ (using a step size of 0.05°2θ and a step time of 0.5 s) as slab samples using as-received powder. Samples were prepared on polished zero-background (510) silicon wafers by gently pressing them onto a flat surface or packing them into cut cavities. The sample was rotated in its own plane. A small D8 disc recess holder was used for sample preparation.
[0050] Bruker D2 Powder X-ray Diffraction Characterization: Powder X-ray diffraction patterns of samples were acquired on a Bruker 2nd Gen D2-Phaser diffractometer using CuKα radiation (30V, 10mA), theta-2theta goniometer, V4 receiving slits, Ge monochromator, and Lynxeye detector. The instrument is performance checked using a certified corundum standard (NIST 1976). Data were collected over an angular range of 2°-35°2θ (using a step size of 0.05°2θ and a step time of 2.0 seconds) or 2°-42°2θ (using a step size of 0.025°2θ and a step time of 5.0 seconds) at ambient temperature. Samples run under ambient conditions were prepared as slab samples using the as-received powder without grinding. Approximately 20 mg of sample was gently loaded into the sample holder and all samples were analyzed using Diffrac Plus EVA v4.2.0.14.
[0051] Differential Scanning Calorimetry (DSC) (TA Q2000): SC data were collected on a TA Instruments Q2000 equipped with a 50-position autosampler. Typically, 0.5-3 mg of each sample was placed in a pinhole aluminum pan and heated from 25 to 300 °C at 10 °C / min. A purge of dry nitrogen was maintained over the samples at 50 ml / min. The instrument control software was Advantage and Thermal Advantage for Q-series, and data were analyzed using Universal Analysis or TRIOS.
[0052] Differential Scanning Calorimetry (DSC) (Pyris 4000): DSC data were collected on a PerkinElmer Pyris 4000 DSC equipped with a 45-position sample holder. Certified indium was used to verify the energy and temperature calibration of the instrument. Predefined amounts (0.5–3.0 mg) of sample were placed in aluminum pans with pinholes and incubated at 20 °C min -1 The sample was heated from 30 to 350°C with a 60 ml / min dry nitrogen purge. -1 The instrument control, data acquisition and analysis were performed by Pyris Software v9.0.1.0203.
[0053] Thermogravimetric Analysis (TGA) (TA Q500): TGA data were collected on a TA Instruments Q500 TGA equipped with a 16-position autosampler. Typically, 5-10 mg of each sample was loaded into pre-tared aluminum DSC pans and heated from ambient to 350 °C at 10 °C / min. A nitrogen purge was maintained on the samples at 60 ml / min. The instrument control software was Advantage and Thermal Advantage for Q-series, and data were analyzed using Universal Analysis or TRIOS.
[0054] Thermogravimetric Analysis (TGA) (Perkin Elmer 4000): TGA data were collected on a Perkin Elmer TGA 4000 system. Energy and temperature calibrations were performed using certified indium. Typically, 2-5 mg of each sample was heated at 20 °C / min in a nitrogen atmosphere maintained at 20 ml / min. The instrument control software was Perkin Elmer Pyris Thermal Analysis v11.1.1.0492. All data analysis was performed using Pyris Thermal Analysis software v13.3.1.0014.
[0055] Solution proton nuclear magnetic resonance ( 1 H-NMR): A JEOL EX 270MHz spectrometer equipped with an autosampler was used. 1 H-NMR spectra were collected. Samples were dissolved in d6-DMSO and analyzed. Data were acquired using Delta NMR Processing and Control Software version 4.3.
[0056] Scanning Electron Microscopy (SEM): Data were collected with a Phenom Pro scanning electron microscope. A small sample was mounted on an aluminum stub using conductive double-sided sticky tape. A thin layer of gold was applied using a sputter coater (20 mA, 120 s).
[0057] Gravimetric Vapor Sorption (GVS): Adsorption isotherms were obtained using an SMS DVS Intrinsic moisture sorption analyzer (controlled by DVS Intrinsic control software). Sample temperature was maintained at 25°C by the instrument controls. Humidity was controlled by mixing dry and humid nitrogen streams with a total flow rate of 200 ml / min. Relative humidity was measured by a calibrated Rotronic probe (dynamic range 1.0-100% RH) placed near the sample. Weight change (mass relaxation) in the sample as a function of %RH was constantly monitored by a microbalance (accuracy ±0.005 mg).
[0058] Typically, 5-30 mg of sample was placed in a tared mesh stainless steel basket under ambient conditions. Samples were loaded and removed at 40% RH and 25°C (typical room conditions). Moisture sorption isotherms were performed as outlined in Table 1 (2 scans per complete cycle). Standard isotherms were run at 25°C over the range 0-90% RH at 10% RH intervals. Typically, double cycles (4 scans) were performed. Data analysis was performed using the DVS Analysis Suite in Microsoft Excel. Samples were collected after completion of the isotherm and reanalyzed by XRPD. [Table 1]
[0059] Karl Fischer titration: The moisture content of each sample was determined using a Metrohm 874 oven sample processor at 150°C and an 851 Titrano coulometer (using Hydranal Coulomat AG oven reagents and nitrogen purge). A weighed amount of solid sample was introduced into a sealed sample vial. Approximately 10 mg of sample was used per titration and duplicate determinations were performed. The average values of these results are shown unless otherwise stated. Data collection and analysis were performed using Tiamo software.
[0060] Chemical purity determination by HPLC: Purity analysis was performed on an Agilent HP1100 / Infinity II 1260 series system equipped with a diode array detector and using OpenLAB software. Complete method details are shown in Table 2. [Table 2]
[0061] Fourier transform infrared spectroscopy: A Perkin-Elmer Spectrum One (equipped with a versatile attenuated total reflectance (ATR) sampling accessory) was used to measure the infrared spectrum from 4000 to 650 cm -1Data was collected over 16 scans at 1000 x 1000 nm using Spectrum software and processed using an ACD Spectrus Processor.
[0062] Example 1: 1:1 Olaparib-Gentisic Acid Cocrystal
[0063] 1.1 Preparation of 1:1 Olaparib Gentisic Acid Cocrystals
[0064] A batch of 1:1 olaparib:gentisic acid cocrystal used for characterization was prepared as follows:
[0065] Olaparib (500 mg, 1.15 mmol) and gentisic acid (178 mg, 1.15 mmol) were milled with acetonitrile (200 μL) in a Retsch MM400 ball mill at 30 Hz for 6×20 min. The product was dried in vacuum at 40° C. for 2 h.
[0066] 1.2 XRPD characterization of 1:1 olaparib gentisic acid cocrystal
[0067] The D8 XRPD pattern of the 1:1 olaparib gentisic acid cocrystal is shown in Figure 1. Table 3 provides the angles, °2θ ± 0.2 °2θ, and d values of the peaks identified in the XRPD pattern of Figure 1. The entire list of peaks or corresponding d values, or a subset thereof, may be sufficient to characterize the cocrystal, also with an XRPD pattern substantially similar to Figure 1. For example, the cocrystal may be characterized by at least two, at least three, at least four, or all of the peaks selected from the peaks at 11.7, 13.2, 15.0, 23.5, and 25.2 °2θ ± 0.2 °2θ. [Table 3-1] [Table 3-2]
[0068] 1.3 DSC of 1:1 olaparib gentisic acid cocrystal
[0069] The DSC trace of the 1:1 olaparib gentisic acid cocrystal obtained on a TA Q2000 instrument (Figure 2) shows a single endotherm with an onset temperature of 155.2°C and a peak maximum of 158.0°C.
[0070] 1.4 TGA of 1:1 olaparib gentisic acid cocrystal
[0071] The TGA trace of the 1:1 olaparib:gentisic acid cocrystal obtained on a TA Q500 instrument (Figure 3) shows no significant weight loss up to 200 °C, at which point a weight loss of 26% is observed (corresponding to the loss of 1 mole of gentisic acid). This indicates that the cocrystal has a 1:1 olaparib:gentisic acid stoichiometry and that the cocrystal is anhydrous.
[0072] 1.5 Infrared spectrum of 1:1 olaparib gentisic acid cocrystal
[0073] The infrared spectrum of the 1:1 olaparib gentisic acid cocrystal is shown in Figure 4. Notable peaks identified in the infrared spectrum of Figure 4 are 3010, 1903, 1665, 1643, 1598, 1557, 1501, 1464, 1438, 1354, 1341, 1259, 1244, 1230, 1200, 1165, 1126, 1021, 1009, 928, 878, 822, 797, 767, 749, 705, and 671 cm. -1 ±1cm -1 The entire list of peaks, or a subset thereof, may be sufficient to characterize the cocrystal, also by an infrared pattern substantially similar to that of FIG.
[0074] Example 2: 2:1 Olaparib Gentisic Acid Cocrystal
[0075] 2.1 Preparation of 2:1 olaparib gentisic acid cocrystal
[0076] A batch of 2:1 olaparib:gentisic acid cocrystal used for characterization was prepared as follows:
[0077] Olaparib (500 mg, 1.15 mmol) and gentisic acid (88 mg, 0.57 mmol) were milled with water (200 μL) in a Retsch MM400 ball mill at 30 Hz for 3×20 min. The product was dried in vacuum at 40° C. for 2 h.
[0078] 2.2 XRPD characterization of the 2:1 olaparib gentisic acid cocrystal
[0079] The D8 XRPD pattern of the 2:1 olaparib gentisic acid cocrystal is shown in Figure 5. Table 4 provides the angles, °2θ ± 0.2 °2θ, and d values of the peaks identified in the XRPD pattern of Figure 5. The entire list of peaks or corresponding d values, or a subset thereof, may be sufficient to characterize the cocrystal, also with an XRPD pattern substantially similar to Figure 5. For example, the cocrystal may be characterized by at least two, at least three, at least four, or all of the peaks selected from the peaks at 6.1, 10.3, 11.6, 12.2, and 20.8 °2θ ± 0.2 °2θ. [Table 4-1] [Table 4-2]
[0080] 2.3 DSC of 2:1 olaparib gentisic acid cocrystal
[0081] The DSC trace of the 2:1 olaparib gentisic acid cocrystal obtained on a TA Q2000 instrument (FIG. 6) shows an endotherm with an onset temperature of 104.4° C. and a peak maximum of 114.8° C., followed by a second broad endotherm with an onset temperature of 165.5° C. and a peak maximum of 182.2° C.
[0082] 2.4 TGA of 2:1 olaparib gentisic acid cocrystal
[0083] The TGA trace of the 2:1 olaparib gentisic acid cocrystal obtained on a TA Q500 instrument (Figure 7) shows a weight loss of 4.6% from room temperature to 120°C.
[0084] 2.5 Infrared spectrum of the 2:1 olaparib gentisic acid cocrystal
[0085] The infrared spectrum of the 2:1 olaparib gentisic acid cocrystal is shown in Figure 8. Notable peaks identified in the infrared spectrum of Figure 8 are 3380, 3239, 3011, 1718, 1662, 1611, 1591, 1266, 1449, 1436, 1373, 1291, 1281, 1244, 1222, 1214, 1198, 1171, 1088, 1031, 1015, 936, 870, 837, 806, 799, 766, 749, 730, and 681 cm. -1 ±1cm -1 The entire list of peaks, or a subset thereof, may also be sufficient to characterize the cocrystal by an infrared pattern substantially similar to that shown in FIG. -1 ±1cm -1 The peaks may be characterized by at least two peaks, at least three peaks, at least four peaks, or all peaks selected from the peaks in
[0086] 2.6 Gravimetric Vapor Sorption (GVS) Analysis of 2:1 Olaparib Gentisic Acid Cocrystal
[0087] The moisture sorption isotherm graph obtained for the 2:1 olaparib gentisic acid cocrystal is shown in Figure 9. The cocrystal was found to reversibly absorb 3.4% w / w in the relative humidity range of 0-90% at 25 °C under nitrogen atmosphere (reversibly absorb 1.6% w / w at 0-5% RH). XRPD analysis of the sample after GVS confirmed that the cocrystal structure was unchanged.
[0088] 2.7 Karl Fischer titration of 2:1 olaparib-gentisic acid cocrystal
[0089] Karl Fischer analysis of the 2:1 olaparib gentisic acid cocrystal showed that the sample contained 5.1% water, which is equivalent to 3 moles of water.
[0090] Example 3: 1:1 Olaparib 2,4-dihydroxybenzoic acid co-crystal
[0091] 3.1 Preparation of 1:1 olaparib-2,4-dihydroxybenzoic acid cocrystals
[0092] A batch of 1:1 olaparib-2,4-dihydroxybenzoic acid cocrystal used for characterization was prepared as follows.
[0093] Olaparib (400 mg, 0.92 mmol) and 2,4-dihydroxybenzoic acid (144 mg, 0.93 mmol) were milled with acetonitrile (200 μL) in a Retsch MM400 ball mill at 30 Hz for 6×20 min. The product was dried in vacuum at 40° C. for 2 h.
[0094] 3.2 XRPD characterization of the 1:1 olaparib-2,4-dihydroxybenzoic acid cocrystal
[0095] The D8 XRPD pattern of the 1:1 olaparib 2,4-dihydroxybenzoic acid co-crystal is shown in Figure 10. Table 5 provides the angles, °2θ ± 0.2 °2θ, and d values of the peaks identified in the XRPD pattern of Figure 10. The entire list of peaks or corresponding d values, or a subset thereof, may be sufficient to characterize the co-crystal, also with an XRPD pattern substantially similar to Figure 10. For example, the co-crystal may be characterized by at least two, at least three, at least four, or all of the peaks selected from the peaks at 3.5, 8.5, 9.4, 11.9, and 16.5 °2θ ± 0.2 °2θ. [Table 5-1] [Table 5-2]
[0096] 3.3 DSC of 1:1 olaparib-2,4-dihydroxybenzoic acid cocrystal
[0097] The DSC trace of the 1:1 olaparib 2,4-dihydroxybenzoic acid co-crystal obtained on a TA Q2000 instrument (FIG. 11) shows an endotherm with an onset temperature of 132.1° C. and a peak maximum of 143.6° C., followed by a second broad endotherm with an onset temperature of 180.1° C. and a peak maximum of 203.1° C.
[0098] 3.4 TGA of 1:1 olaparib-2,4-dihydroxybenzoic acid cocrystal
[0099] The TGA trace of the 1:1 olaparib 2,4-dihydroxybenzoic acid co-crystal obtained on a TA Q500 instrument (FIG. 12) shows no significant weight loss up to 150° C.
[0100] 3.5 Infrared spectrum of 1:1 olaparib-2,4-dihydroxybenzoic acid cocrystal
[0101] The infrared spectrum of the 1:1 olaparib 2,4-dihydroxybenzoic acid cocrystal is shown in Figure 13. Notable peaks identified in the infrared spectrum of Figure 13 are 3172, 3012, 2907, 1677, 1645, 1620, 1594, 1599, 1496, 1471, 1436, 1347, 1260, 1321, 1212, 1200, 1141, 1088, 1028, 1008, 975, 964, 935, 834, 806, 797, 768, 729, and 680 cm. -1 ±1cm -1 The entire list of peaks, or a subset thereof, may be sufficient to characterize the cocrystal, also by an infrared pattern substantially similar to that of FIG.
[0102] Example 4: 2:1 Olaparib 2,4-dihydroxybenzoic acid cocrystal
[0103] 4.1 Preparation of 2:1 olaparib-2,4-dihydroxybenzoic acid cocrystals
[0104] A batch of 2:1 olaparib-2,4-dihydroxybenzoic acid cocrystal used for characterization was prepared as follows.
[0105] Olaparib (500 mg, 1.15 mmol) and 2,4-dihydroxybenzoic acid (90 mg, 0.58 mmol) were milled with water (100 μL) and ethanol (100 μL) in a Retsch MM400 ball mill at 30 Hz for 3×20 min. The product was dried in vacuum at 40° C. for 2 h.
[0106] 4.2 XRPD characterization of the 2:1 olaparib-2,4-dihydroxybenzoic acid cocrystal
[0107] The D8 XRPD pattern of the 2:1 olaparib 2,4-dihydroxybenzoic acid co-crystal is shown in Figure 14. Table 6 provides the angles, °2θ ± 0.2 °2θ, and d values of the peaks identified in the XRPD pattern of Figure 14. The entire list of peaks or corresponding d values, or a subset thereof, may be sufficient to characterize the co-crystal, also with an XRPD pattern substantially similar to Figure 14. For example, the co-crystal may be characterized by at least two, at least three, at least four, or all of the peaks selected from the peaks at 6.1, 11.6, 13.5, 15.7, and 19.9 °2θ ± 0.2 °2θ. [Table 6-1] [Table 6-2]
[0108] 4.3 DSC of 2:1 olaparib-2,4-dihydroxybenzoic acid cocrystal
[0109] The DSC trace of the 2:1 olaparib 2,4-dihydroxybenzoic acid co-crystal obtained on a TA Q2000 instrument (FIG. 15) shows a major endotherm with an onset temperature of 111.8° C. and a peak maximum of 117.5° C. This is followed by a second endotherm with an onset temperature of 175.3° C. and a peak maximum of 183.0° C., and a third endotherm with an onset temperature of 193.5° C. and a peak maximum of 208.4° C.
[0110] 4.4 TGA of 2:1 Olaparib-2,4-dihydroxybenzoic acid cocrystal
[0111] The TGA trace of the 2:1 olaparib 2,4-dihydroxybenzoic acid co-crystal obtained on a TA Q500 instrument (FIG. 16) shows a weight loss of 4.6% between 40° C. and 125° C.
[0112] 4.5 Infrared spectrum of 2:1 olaparib-2,4-dihydroxybenzoic acid cocrystal
[0113] The infrared spectrum of the 2:1 olaparib 2,4-dihydroxybenzoic acid cocrystal is shown in Figure 17. Notable peaks identified in the infrared spectrum of Figure 17 are 3268, 3011, 1656, 1608, 1590, 1464, 1435, 1349, 1337, 1243, 1221, 1181, 1173, 1114, 1096, 1027, 1014, 976, 936, 838, 805, 797, 750, 729, 706, 693, and 657 cm. -1 ±1cm -1 The entire list of peaks, or a subset thereof, may also be sufficient to characterize the cocrystal by an infrared pattern substantially similar to that shown in FIG. 17. For example, the cocrystal may have peaks at 1014, 1222, 1243, 1435, and 1590 cm. -1 ±1cm -1 The peaks may be characterized by at least two, at least three, at least four, or all of the peaks selected from the peaks in
[0114] 4.6 Gravimetric Vapor Sorption (GVS) Analysis of the 2:1 Olaparib-2,4-Dihydroxybenzoic Acid Cocrystal
[0115] The moisture sorption isotherm graph obtained for the 2:1 olaparib-2,4-dihydroxybenzoic acid cocrystal is shown in Figure 18. The cocrystal was found to reversibly absorb 4.5% w / w in the relative humidity range of 0-90% at 25 °C under nitrogen atmosphere (reversibly absorb 2.5% w / w at 0-5% RH). XRPD analysis of the sample after GVS confirmed that the cocrystal structure was unchanged.
[0116] 4.7 Karl Fischer titration of 2:1 olaparib-2,4-dihydroxybenzoic acid cocrystal
[0117] Karl Fischer analysis of the 2:1 olaparib-2,4-dihydroxybenzoic acid cocrystal showed the sample contained 5.5% water, which corresponds to 3.2 moles of water.
[0118] Example 5: 2:1 Olaparib 4-hydroxybenzoic acid cocrystal
[0119] 5.1 Preparation of 2:1 olaparib-4-hydroxybenzoic acid cocrystal
[0120] A batch of 2:1 olaparib-4-hydroxybenzoic acid cocrystal used for characterization was prepared as follows.
[0121] Olaparib (500 mg, 1.15 mmol) and 4-hydroxybenzoic acid (79 mg, 0.57 mmol) were milled with water (200 μL) in a Retsch MM400 ball mill at 30 Hz for 3×20 min. The product was dried in vacuum at 40° C. for 2 h.
[0122] 5.2 XRPD characterization of the 2:1 olaparib-4-hydroxybenzoic acid cocrystal
[0123] The D8 XRPD pattern of the 2:1 olaparib 4-hydroxybenzoic acid cocrystal is shown in Figure 19. Table 7 provides the angles, °2θ ± 0.2 °2θ, and d values of the peaks identified in the XRPD pattern of Figure 19. The entire list of peaks or corresponding d values, or a subset thereof, may be sufficient to characterize the cocrystal, also with an XRPD pattern substantially similar to Figure 19. For example, the cocrystal may be characterized by at least two, at least three, at least four, or all of the peaks selected from the peaks at 6.3, 13.6, 15.9, 19.8, and 21.6 °2θ ± 0.2 °2θ. [Table 7]
[0124] 5.3 DSC of 2:1 olaparib-4-hydroxybenzoic acid cocrystal
[0125] The DSC trace of the 2:1 olaparib 4-hydroxybenzoic acid co-crystal obtained on a TA Q2000 instrument (FIG. 20) shows a major endotherm with an onset temperature of 97.7° C. and a peak maximum of 106.3° C., followed by a second broad endotherm with an onset temperature of 154.4° C. and a peak maximum of 182.8° C.
[0126] 5.4 TGA of 2:1 Olaparib-4-hydroxybenzoic acid cocrystal
[0127] The TGA trace of the 2:1 olaparib-4-hydroxybenzoic acid co-crystal obtained on a TA Q500 instrument (FIG. 21) shows a weight loss of 4.4% from room temperature to 120° C.
[0128] 5.5 Infrared spectrum of the 2:1 olaparib-4-hydroxybenzoic acid cocrystal
[0129] The infrared spectrum of the 2:1 olaparib 4-hydroxybenzoic acid cocrystal is shown in Figure 22. Prominent peaks identified in the infrared spectrum of Figure 22 are 3266, 1684, 1655, 1619, 1608, 1589, 1464, 1447, 1435, 1373, 1349, 1310, 1277, 1256, 1243, 1222, 162, 1099, 1059, 936, 868, 806, 784, 751, 729, 705, 693, and 664 cm. -1 ±1cm -1 The entire list of peaks, or a subset thereof, may also be sufficient to characterize the cocrystal by an infrared pattern substantially similar to that shown in FIG. 22. For example, the cocrystal may have peaks at 1014, 1222, 1243, 1435, and 1590 cm. -1 ±1cm -1 The peaks may be characterized by at least two, at least three, at least four, or all of the peaks selected from the peaks in
[0130] 5.6 Gravimetric Vapor Sorption (GVS) Analysis of the 2:1 Olaparib-4-hydroxybenzoic Acid Cocrystal
[0131] The moisture sorption isotherm obtained for the 2:1 olaparib-4-hydroxybenzoic acid cocrystal is shown in Figure 23. The cocrystal was found to reversibly absorb 3.4% w / w in the relative humidity range of 0-90% at 25 °C under nitrogen atmosphere (reversibly absorb 1.5% w / w at 0-5% RH). XRPD analysis of the sample after GVS confirmed that the cocrystal structure was unchanged.
[0132] 5.7 Karl Fischer titration of 2:1 olaparib-4-hydroxybenzoic acid cocrystal
[0133] Karl Fischer analysis of the 2:1 olaparib-4-hydroxybenzoic acid cocrystal showed that the sample contained 4.8% water, which corresponds to 2.9 moles of water.
[0134] Example 6: 1:1 Olaparib Salicylic Acid Cocrystal
[0135] 6.1 Preparation of 1:1 Olaparib-salicylic acid cocrystal
[0136] A batch of crystalline 1:1 olaparib:salicylic acid cocrystal used for characterization was prepared as follows:
[0137] Olaparib (208 mg, 0.48 mmol) and salicylic acid (66 mg, 0.48 mmol) were milled with nitromethane (3 drops) in a Retsch MM400 ball mill at 30 Hz for 5 x 15 min. The product was dried in vacuum at 40°C for 1 h.
[0138] 6.2 XRPD characterization of the 1:1 olaparib-salicylic acid cocrystal
[0139] The D2 XRPD pattern of the 1:1 olaparib salicylic acid cocrystal is shown in Figure 24. Table 8 provides the angles, °2θ ± 0.2 °2θ, and d values of the peaks identified in the XRPD pattern of Figure 24. The entire list of peaks or corresponding d values, or a subset thereof, may be sufficient to characterize the cocrystal, also with an XRPD pattern substantially similar to Figure 24. For example, the cocrystal may be characterized by at least two, at least three, at least four, or all of the peaks selected from the peaks at 8.4, 9.3, 12.5, 13.3, and 16.7 °2θ ± 0.2 °2θ. [Table 8]
[0140] 6.3 DSC of 1:1 Olaparib-salicylic acid cocrystal
[0141] The DSC trace of the 1:1 olaparib salicylic acid cocrystal obtained on a Pyris 4000 instrument (FIG. 25) shows a major endotherm with a peak maximum at 146.4 °C.
[0142] 6.4 TGA of 1:1 Olaparib-salicylic acid cocrystal
[0143] The TGA trace of the 1:1 olaparib-salicylic acid cocrystal obtained on a Perkin Elmer 4000 instrument (FIG. 26) shows no significant weight loss up to 150° C., at which point a weight loss of 24% is observed (corresponding to the loss of 1 mole of salicylic acid), indicating that the cocrystal has a 1:1 olaparib:salicylic acid stoichiometry and that the cocrystal is anhydrous.
[0144] Example 7: 1:1 Olaparib 3,4-dihydroxybenzoic acid co-crystal
[0145] 7.1 Preparation of 1:1 olaparib-3,4-dihydroxybenzoic acid cocrystal
[0146] A batch of crystalline 1:1 olaparib-3,4-dihydroxybenzoic acid co-crystal used for characterization was prepared as follows.
[0147] Olaparib (74 mg, 0.17 mmol) and 3,4-dihydroxybenzoic acid (26 mg, 0.17 mmol) were placed in a glass vial and water saturated with 3,4-dihydroxybenzoic acid (3 ml) was added. The resulting slurry was placed in a shaker and aged for 2 days (8 hour cycle from room temperature to 50° C., heated to 50° C. for 4 hours, then cooled to room temperature for an additional 4 hours). The product was then filtered under vacuum and dried in vacuum at 40° C. for 8 hours.
[0148] 7.2 XRPD Characterization of 1:1 Olaparib-3,4-Dihydroxybenzoic Acid Cocrystal
[0149] A D2 XRPD pattern of the 1:1 olaparib-3,4-dihydroxybenzoic acid co-crystal obtained on a Bruker 2nd Gen D2-Phaser diffractometer is shown in Figure 27. Table 9 provides the angles, °2θ ± 0.2 °2θ, and d values of the peaks identified in the XRPD pattern of Figure 27. The entire list of peaks or corresponding d values, or a subset thereof, may also be sufficient to characterize the co-crystal with an XRPD pattern substantially similar to Figure 27. For example, the co-crystal may be characterized by at least two, at least three, at least four, or all of the peaks selected from the peaks at 9.4, 11.7, 16.0, 17.4, and 19.9 °2θ ± 0.2 °2θ. [Table 9]
[0150] 7.3 DSC of 1:1 olaparib-3,4-dihydroxybenzoic acid cocrystal
[0151] The DSC trace of the 1:1 olaparib-3,4-dihydroxybenzoic acid cocrystal obtained on a Pyris 4000 instrument (FIG. 28) shows a broad endotherm with a peak maximum at 93.2° C. The broad endotherm shows two small shoulder peaks above and below the temperature of the peak maximum.
[0152] 7.4 TGA of 1:1 Olaparib-3,4-dihydroxybenzoic acid cocrystal
[0153] The TGA trace of the 1:1 olaparib-3,4-dihydroxybenzoic acid co-crystal obtained on a Perkin Elmer 4000 instrument (FIG. 29) shows a weight loss of approximately 2.3% between 45° C. and 95° C., corresponding to 0.8 moles of water, suggesting the presence of water trapped within the crystal structure of the 1:1 olaparib-3,4-dihydroxybenzoic acid co-crystal.
[0154] 7.5 1:1 Olaparib-3,4-dihydroxybenzoic acid cocrystal 1 H NMR spectrum
[0155] The 1:1 olaparib-3,4-dihydroxybenzoic acid cocrystal shown in FIG. 1 The H NMR spectrum shows the following peaks: 1 H NMR (400MHz, DMSO): δ 0.65-0.80 (4H), 1.80-2.05 (1H), 3.05-3.25 (2H), 3.40-3.80 (6H), 4.33 (2H), 6.75-6.80 (1H), 7.20-7.30 (2H), 7.30-7.35 (1H), 7.35-7.45 (1H), 7.40-7.50 (1H), 7.80-7.85 (1H), 7.85-7.95 (1H), 7.95-8.00 (1H), 8.20-8.30 (1H), and 12.60 (1H). 1 The peak at 6.75-6.80 ppm in the H NMR spectrum corresponds to one proton of 3,4-dihydroxybenzoic acid. Comparison of the integral of this peak with the integral of the peak at 1.80-2.05 ppm corresponding to one proton of olaparib indicates that the cocrystal has a 1:1 API:coformer stoichiometry.
[0156] Example 8: Solid-state stability study of olaparib hydroxybenzoic acid cocrystals
[0157] Tests were conducted to examine the physical stability of olaparib hydroxybenzoic acid cocrystals for signs of solid-state form transformation or decomposition over time under accelerated storage conditions. 1:1 olaparib gentisic acid cocrystal, 2:1 olaparib gentisic acid cocrystal, 1:1 olaparib 2,4-dihydroxybenzoic acid cocrystal, 2:1 2,4-dihydroxybenzoic acid cocrystal, and 2:1 olaparib 4-hydroxybenzoic acid cocrystal were stored separately at 40° C. / 75% relative humidity and 25° C. / 97% relative humidity for 7 days. After this time, all samples remained white solids and showed no signs of deliquescence. Each sample was analyzed by XRPD to observe any potential form changes and by HPLC to determine purity and to quantify any signs of decomposition. The results of the tests are shown in Table 10. [Table 10]
[0158] Table 10 shows that after seven days of storage under accelerated conditions, all co-crystals retained their original crystalline morphology and none of the olaparib hydroxybenzoic acid co-crystals of the invention underwent solid form conversion or dissociation under these conditions. All co-crystals showed little signs of decomposition when exposed to these accelerated storage conditions, as quantified by HPLC purity analysis.
[0159] Example 9: Dissolution Test
[0160] As explained in US2018 / 0113216, the oral bioavailability of olaparib depends on both the dissolution rate and the overall solubility of the drug in the gastrointestinal (GI) tract. US2018 / 0113216 describes how olaparib has a tendency to be effluxed by P-gp at concentrations that limit its permeability and its absorption from the GI tract. This efflux rate decreases as the concentration of the drug in solution increases. Therefore, to minimize this efflux problem and achieve optimal absorption and bioavailability, it is essential to find a form of olaparib that has the highest possible dissolution rate in the GI tract and maintains a high level of solubility for a sufficient period of time to allow the drug to be absorbed into the bloodstream. Therefore, studies were conducted to investigate the dissolution rates of 1:1 olaparib gentisic acid cocrystal, 2:1 olaparib gentisic acid cocrystal, 1:1 olaparib 2,4-dihydroxybenzoic acid cocrystal, 2:1 2,4-dihydroxybenzoic acid cocrystal, and 2:1 olaparib 4-hydroxybenzoic acid cocrystal compared to pure crystalline olaparib form A (as supplied) 2-20 μm and milled crystalline olaparib form A 0.5-5 μm. Dissolution studies were performed using 50 mL of simulated intestinal fluid (FaSSIF V2) at pH 6.5 (37° C.) using an amount of each olaparib equivalent to 25 mg of olaparib. The dissolution studies were performed using a Pion inForm® instrument. Detection and quantification of olaparib was performed by in-situ UV spectroscopy using a fiber optic probe, which allowed for instantaneous data collection from the time of sample introduction. The amount of dissolved drug was quantified by converting the UV absorbance data to mg / mL (±0.2 mg / mL) using a previously determined pH-dependent molar extinction coefficient.
[0161] The results of this study are shown in Figure 31. The dissolution rates of all hydroxybenzoic acid co-crystals in this study were higher than either crystalline Olaparib Form A (as supplied) or milled Olaparib Form A, and all hydroxybenzoic acid co-crystals achieved higher levels of dissolution than Olaparib Form A in the simulated intestinal medium with minimal loss of dissolution over the 60 minute period. Although reducing particle size by milling is a recognized method for increasing the dissolution rate of poorly soluble drugs, Figure 31 shows that reducing the particle size of Olaparib Form A resulted in a slower dissolution rate as well as an overall decrease in the amount of Olaparib dissolved at any time point over the 30 minute time period.
[0162] FIG. 32 shows an XRPD overlay of the 2:1 olaparib gentisic acid co-crystal, the 2:1 2,4-dihydroxybenzoic acid co-crystal, and the 2:1 olaparib·4-hydroxybenzoic acid co-crystal.
Claims
1. A 1:1 olaparib:hydroxybenzoic acid co-crystal, wherein the hydroxybenzoic acid is a compound of formula (I): 【Chemistry 1】 Wherein n=0 or 1; With the proviso that when n=1, the hydroxyl groups are not at the 3- and 5-positions of the benzene ring.
2. 2:1 olaparib:hydroxybenzoic acid co-crystal, wherein the hydroxybenzoic acid is a compound of formula (II): 【Chemistry 2】 wherein n=0 or 1.
3. 3. The 2:1 olaparib:hydroxybenzoic acid cocrystal of claim 2, wherein the cocrystal is hydrated.
4. 4. The 2:1 olaparib:hydroxybenzoic acid cocrystal of claim 3, wherein the cocrystal contains up to about one water of hydration.
5. 4. The 2:1 olaparib:hydroxybenzoic acid cocrystal of claim 3, wherein the cocrystal contains up to about 2 waters of hydration.
6. 4. The 2:1 olaparib:hydroxybenzoic acid cocrystal of claim 3, wherein the cocrystal contains up to about 3 waters of hydration.
7. 2. The 1:1 olaparib:hydroxybenzoic acid cocrystal of claim 1, wherein the cocrystal is selected from the group consisting of a 1:1 olaparib gentisic acid cocrystal, a 1:1 olaparib 2,4-dihydroxybenzoic acid cocrystal, a 1:1 olaparib salicylic acid cocrystal, and a 1:1 olaparib 3,4-dihydroxybenzoic acid cocrystal.
8. 7. The 2:1 olaparib:hydroxybenzoic acid cocrystal of any of claims 2-6, wherein the cocrystal is selected from the group consisting of a 2:1 olaparib gentisic acid cocrystal, a 2:1 olaparib 2,4-dihydroxybenzoic acid cocrystal, and a 2:1 olaparib 4-hydroxybenzoic acid cocrystal.
9. 7. The 2:1 olaparib:hydroxybenzoic acid cocrystal of any one of claims 2-6, wherein the cocrystal is characterized by an X-ray powder diffraction pattern having at least two, at least three, at least four, or all of the peaks selected from the peaks at 6.2, 10.3, 11.6, 13.5, and 17.8 °2θ±0.2 °2θ.
10. The cocrystal has peaks at 1014, 1222, 1243, 1435, and 1590 cm -1 ±1cm -1 7. The 2:1 olaparib:hydroxybenzoic acid cocrystal of any one of claims 2 to 6, characterized by an infrared spectrum having at least two, at least three, at least four, or all of the peaks selected from the peaks in
11. 8. The 1:1 olaparib:hydroxybenzoic acid cocrystal of claim 7, wherein the cocrystal is a 1:1 olaparib gentisic acid cocrystal characterized by at least one of the following: an X-ray powder diffraction pattern having at least two, at least three, at least four, or all of the peaks selected from the peaks at 11.7, 13.2, 15.0, 23.5, and 25.2 °2θ±0.2 °2θ; or A powder X-ray diffraction pattern substantially similar to that shown in FIG.
12. 12. The 1:1 olaparib:hydroxybenzoic acid cocrystal of claim 11, wherein the powder X-ray diffraction pattern has at least three peaks selected from peaks at 11.7, 13.2, 15.0, 23.5, and 25.2 °2θ±0.2 °2θ.
13. 9. The 2:1 olaparib:hydroxybenzoic acid cocrystal of claim 8, wherein the cocrystal is a 2:1 olaparib gentisic acid cocrystal characterized by at least one of the following: an X-ray powder diffraction pattern having at least two, at least three, at least four, or all of the peaks selected from the peaks at 6.1, 10.3, 11.6, 12.2, and 20.8 °2θ±0.2 °2θ; or A powder X-ray diffraction pattern substantially similar to that of FIG.
14. 8. The 1:1 olaparib:hydroxybenzoic acid cocrystal of claim 7, wherein the cocrystal is a 1:1 olaparib-2,4-dihydroxybenzoic acid cocrystal characterized by at least one of the following: an X-ray powder diffraction pattern having at least two, at least three, at least four, or all of the peaks selected from the peaks at 3.5, 8.5, 9.4, 11.9, and 16.5°2θ±0.2°2θ; or A powder X-ray diffraction pattern substantially similar to that of FIG.
15. 15. The 1:1 olaparib:hydroxybenzoic acid cocrystal of claim 14, wherein the powder X-ray diffraction pattern has at least three peaks selected from peaks at 3.5, 8.5, 9.4, 11.9, and 16.5 °2θ±0.2 °2θ.
16. 9. The 2:1 olaparib:hydroxybenzoic acid cocrystal of claim 8, wherein the cocrystal is a 2:1 olaparib-2,4-dihydroxybenzoic acid cocrystal characterized by at least one of the following: an X-ray powder diffraction pattern having at least two, at least three, at least four, or all of the peaks selected from the peaks at 6.1, 11.6, 13.5, 15.7, and 19.9 °2θ±0.2 °2θ; or A powder X-ray diffraction pattern substantially similar to that of FIG.
17. 9. The 2:1 olaparib:hydroxybenzoic acid cocrystal of claim 8, wherein the cocrystal is a 2:1 olaparib-4-hydroxybenzoic acid cocrystal characterized by at least one of the following: an X-ray powder diffraction pattern having at least two, at least three, at least four, or all of the peaks selected from the peaks at 6.3, 13.6, 15.9, 19.8, and 21.6 °2θ±0.2 °2θ; or A powder X-ray diffraction pattern substantially similar to that of FIG.
18. 8. The 1:1 olaparib:hydroxybenzoic acid cocrystal of claim 7, wherein the cocrystal is a 1:1 olaparib-salicylic acid cocrystal characterized by at least one of the following: an X-ray powder diffraction pattern having at least two, at least three, at least four, or all of the peaks selected from the peaks at 8.4, 9.3, 12.5, 13.3, and 16.7 °2θ±0.2 °2θ; or A powder X-ray diffraction pattern substantially similar to that in FIG.
19. 20. The 1:1 olaparib:hydroxybenzoic acid cocrystal of claim 18, wherein the powder X-ray diffraction pattern has at least three peaks selected from peaks at 8.4, 9.3, 12.5, 13.3, and 16.7 °2θ± 0.2 °2θ.
20. 8. The 1:1 olaparib:hydroxybenzoic acid cocrystal of claim 7, wherein the cocrystal is a 1:1 olaparib-3,4-dihydroxybenzoic acid cocrystal characterized by at least one of the following: an X-ray powder diffraction pattern having at least two, at least three, at least four, or all of the peaks selected from the peaks at 9.4, 11.7, 16.0, 17.4, and 19.9 °2θ±0.2 °2θ; or A powder X-ray diffraction pattern substantially similar to that in FIG.
21. 21. The 1:1 olaparib:hydroxybenzoic acid cocrystal of claim 20, wherein the powder X-ray diffraction pattern has at least three peaks selected from peaks at 9.4, 11.7, 16.0, 17.4, and 19.9 °2θ± 0.2 °2θ.
22. 27. A pharmaceutical composition comprising the 1:1 olaparib:hydroxybenzoic acid cocrystal of any one of claims 1, 7, 11, 12, 14, 15, or 18-21, or the 2:1 olaparib:hydroxybenzoic acid cocrystal of any one of claims 2-6, 8-10, 13, 16, or 17, and a pharma- ceutically acceptable carrier.
23. 23. A method of treating a disease, disorder, or condition through the inhibition of poly(ADP-ribose) polymerase (PARP), comprising administering to a subject in need thereof a therapeutically effective amount of a 1:1 olaparib:hydroxybenzoic acid cocrystal of any one of claims 1, 7, 11, 12, 14, 15, or 18-21, a 2:1 olaparib:hydroxybenzoic acid cocrystal of any one of claims 2-6, 8-10, 13, 16, or 17, or a pharmaceutical composition of claim 22.
24. 23. A method of treating cancer, fibrosis, an inflammatory condition, a neurological disease, a cardiovascular condition, an ocular degenerative disease, a vascular disease, or a serious disease selected from the group of septic shock, acute lung injury (ALI), and acute liver failure, comprising administering to a subject in need thereof a therapeutically effective amount of the 1:1 olaparib:hydroxybenzoic acid cocrystal of any one of claims 1, 7, 11, 12, 14, 15, or 18-21, the 2:1 olaparib:hydroxybenzoic acid cocrystal of any one of claims 2-6, 8-10, 13, 16, or 17, or the pharmaceutical composition of claim 22.
25. 23. Use of the 1:1 olaparib:hydroxybenzoic acid co-crystal of any one of claims 1, 7, 11, 12, 14, 15, or 18-21, the 2:1 olaparib:hydroxybenzoic acid co-crystal of any one of claims 2-6, 8-10, 13, 16, or 17, or the pharmaceutical composition of claim 22, for treating a disease, disorder, or condition through the inhibition of poly(ADP-ribose) polymerase (PARP).
26. 23. Use of the 1:1 olaparib:hydroxybenzoic acid cocrystal of any one of claims 1, 7, 11, 12, 14, 15, or 18-21, the 2:1 olaparib:hydroxybenzoic acid cocrystal of any one of claims 2-6, 8-10, 13, 16, or 17, or the pharmaceutical composition of claim 22, for the treatment of cancer, fibrosis, an inflammatory condition, a neurological disease, a cardiovascular condition, an ocular degenerative disease, a vascular disease, or a serious disease selected from the group of septic shock, acute lung injury (ALI), and acute liver failure.
27. 13. A method for preparing a 1:1 olaparib:hydroxybenzoic acid co-crystal or a 2:1 olaparib:hydroxybenzoic acid co-crystal, comprising slurrying a mixture of olaparib and a hydroxybenzoic acid according to claim 1 or 2 in a solvent.
28. 13. A method for preparing a 1:1 olaparib:hydroxybenzoic acid cocrystal or a 2:1 olaparib:hydroxybenzoic acid cocrystal, comprising milling a mixture of olaparib and a hydroxybenzoic acid according to claim 1 or 2.
